We have successfully obtained our certification under the new In Vitro Diagnostic Regulation (IVDR; 2017/746)! The first batch of flagship products are already available on the market under the new IVDR, well in advance of the transition period deadline. Read more.
D007 Acute Lymphoblastic Leukemia was recognized as a valuable tool for enhanced molecular testing of adult ALL cases in work shown recently at a scientific congress. Read more.
The external test phase for digitalMLPA assay NXtec D011 Cardiac Panel is about to start, and we are looking for test labs. Read more.
Our digitalMLPA™ portfolio is about to receive an update with the upcoming launch of NXtec D008 DMD – our first dedicated neuromuscular digitalMLPA assay. Read more.
Visit us at booth 404 during ESHG 2026, taking place 13-16 June in Gothenburg (Sweden), and discover how our products can support critical clinical questions and accelerate your research. Read more.
A recent study by researchers at the Hacettepe University highlights how D001 Hereditary Cancer Panel 1 provide clinically relevant insights where standard NGS falls short. Read more.
MRC Holland is looking for DNA samples for the development and quality control of our many products.
We are pleased to share an important update to our Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) portfolio. Improved versions of our MLPA assays for DMD copy number analysis are now available, offering enhanced performance and quality control. Read more.
We are proud to introduce NXtec D028 Carrier Panel 1 - a high-throughput assay detecting CNVs and selected SNVs for carrier status analysis. Read more.
As we look back on 2025, we are excited to share some of the year’s highlights with you! Read more.
Join our mailing list to receive the latest information about our products, technologies and website.